Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
CP+ Analysis

Jasper's IgAN readout nears as small-cap biotechs fund through deals and sales

Jasper has completed IgAN cohort enrolment, closed its Kira deal and reports $135.3M in cash. Its Q4 interim readout lands as buyers pick up small and mid-cap assets.

18 Nov 2026 · CompePharma editorial

What happened

Jasper Therapeutics (JSPR) used its Q3 2026 update to report three things: it has completed enrolment of the IgA nephropathy (IgAN) cohort in its Phase 2 renal basket study of vensobafusp alfa, the Kira deal has closed, and cash stands at $135.3M. Interim IgAN data are expected in the fourth quarter.

The sequence matters. Enrolment is complete, so the readout is now a matter of timing rather than recruitment risk. The balance sheet is stated at a specific figure as the transaction closes. The material provided does not give the terms of the Kira transaction, so we do not characterise its economics or what Jasper gave or received.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Sources

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More CP+ AnalysisAll →